This was accompanied by upregulation of FABP4 and HSL , alongside reduced receptor for advanced glycation end products ( RAGE ) expression, suggesting enhanced lipid turnover and improved adipocyte function
Clinical Points GLP-1 receptor agonists (GLP-1 RAs), such as exenatide, demonstrated efficacy in reducing heavy drinking days and total alcohol intake in individuals with obesity-related alcohol use disorders, suggesting a potential role for GLP-1 RAs in targeted treatments for alcohol dependency, particularly in patients with specific metabolic profiles
The proposed class action asserts claims centered on false advertising and consumer protection theories
The transition between medications is well-studied and generally well tolerated
Morley, J
If people on obesity medication are responsible for household food purchases, they may buy different products for family members as well, such as fewer sugary drinks or snacks